Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol
Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53912#.VNsLbyzQrzE
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=53912#.VNsLbyzQrzE
Affiliation(s)
1The
Lautenberg Center for General and Tumor Immunology, The Hadassah
Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.
2Department of Medicinal and Natural Products, Institute for Drug Research, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.
2Department of Medicinal and Natural Products, Institute for Drug Research, The Hadassah Medical School, The Hebrew University of Jerusalem, Jerusalem, Israel.
ABSTRACT
Cannabidiol (CBD), a major constituent of Cannabis,
has been shown to be a powerful anti-inflammatory and anti-anxiety
drug, without exerting a psychotropic effect. However, when given either
intraperitoneally or orally as a purified product, a bell-shaped
dose-response was observed, which limits its clinical use. In the
present study, we have studied in mice the anti-inflammatory and
anti-nociceptive activities of standardized plant extracts derived from
the Cannabis sativa L., clone 202, which is highly enriched in
CBD and hardly contains any psychoactive ingredients. In stark contrast
to purified CBD, the clone 202 extract, when given either
intraperitoneally or orally, provided a clear correlation between the
anti-inflammatory and anti-nociceptive responses and the dose, with
increasing responses upon increasing doses, which makes this plant
medicine ideal for clinical uses. The clone 202 extract reduced
zymosan-induced paw swelling and pain in mice, and prevented TNFα
production in vivo. It is likely that other components in the extract
synergize with CBD to achieve the desired anti-inflammatory action that
may contribute to overcoming the bell-shaped dose-response of purified
CBD. We therefore propose that Cannabis clone 202 (Avidekel) extract is superior over CBD for the treatment of inflammatory conditions.
Cite this paper
References
Gallily, R. , Yekhtin, Z. and Hanuš, L. (2015) Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology & Pharmacy, 6, 75-85. doi: 10.4236/pp.2015.62010.
| [1] | Hazekamp,
A., Ware, M.A., Muller-Vahl, K.R., Abrams, D. and Grotenhermen, F.
(2013) The Medicinal Use of Cannabis and Cannabinoids—An International
Cross-Sectional Survey on Administration Forms. Journal of Psychoactive
Drugs, 45, 199-210. http://dx.doi.org/10.1080/02791072.2013.805976 |
| [2] | Mechoulam, R. (2012) Cannabis—A Valuable Drug That Deserves Better Treatment. Mayo Clinic Proceedings, 87, 107-109. http://dx.doi.org/10.1016/j.mayocp.2011.12.002 |
| [3] | Greydanus,
D.E., Hawver, E.K., Greydanus, M.M. and Merrick, J. (2013) Marijuana:
Current Concepts. Frontiers in Public Health, 1, 42. http://dx.doi.org/10.3389/fpubh.2013.00042 |
| [4] | Syed,
Y.Y., McKeage, K. and Scott, L.J. (2014)
Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use
in Patients with Moderate to Severe Spasticity Due to Multiple
Sclerosis. Drugs, 74, 563-578. http://dx.doi.org/10.1007/s40265-014-0197-5 |
| [5] | Brenneisen,
R. (2007) Chemistry and Analysis of Phytocannabinoids and Other
Cannabis Constituents. Marijuana and the Cannabinoids, Chapter 2, 17-49.
http://dx.doi.org/10.1007/978-1-59259-947-9_2 |
| [6] | Pertwee,
R.G. (2008) The Diverse CB1 and CB2 Receptor Pharmacology of Three
Plant Cannabinoids: Delta9-Tetrahydrocannabinol, Cannabidiol and
Delta9-Tetrahydrocannabivarin. British Journal of Pharmacology, 153,
199-215. http://dx.doi.org/10.1038/sj.bjp.0707442 |
| [7] | Pacher,
P. and Mechoulam, R. (2011) Is Lipid Signaling through Cannabinoid 2
Receptors Part of a Protective System? Progress in Lipid Research, 50,
193-211. http://dx.doi.org/10.1016/j.plipres.2011.01.001 |
| [8] | Malfait,
A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E.,
Mechoulam, R. and Feldmann, M. (2000) The Nonpsychoactive Cannabis
Constituent Cannabidiol Is an Oral Anti-Arthritic Therapeutic in Murine
Collagen-Induced Arthritis. Proceedings of the National Academy of
Sciences USA, 97, 9561-9566. http://dx.doi.org/10.1073/pnas.160105897 |
| [9] | Mechoulam,
R., Peters, M., Murillo-Rodriguez, E. and Hanus, L.O. (2007)
Cannabidiol—Recent Advances. Chemistry & Biodiversity, 4, 1678-1692.
http://dx.doi.org/10.1002/cbdv.200790147 |
| [10] | Weiss,
L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R. and
Gallily, R. (2008) Cannabidiol Arrests Onset of Autoimmune Diabetes in
NOD Mice. Neuropharmacology, 54, 244-249. http://dx.doi.org/10.1016/j.neuropharm.2007.06.029 |
| [11] | Kozela,
E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R.,
Ben-Nun, A., Juknat, A. and Vogel, Z. (2011) Cannabidiol Inhibits
Pathogenic T Cells, Decreases Spinal Microglial Activation and
Ameliorates Multiple Sclerosis-Like Disease in C57BL/6 Mice. British
Journal of Pharmacology, 163, 1507-1519. http://dx.doi.org/10.1111/j.1476-5381.2011.01379.x |
| [12] | Esposito,
G., Filippis, D.D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C.,
Steardo, A., Cuomo, R. and Steardo, L. (2013) Cannabidiol in
Inflammatory Bowel Diseases: A Brief Overview. Phytotherapy Research,
27, 633-636. http://dx.doi.org/10.1002/ptr.4781 |
| [13] | Jamontt,
J.M., Molleman, A., Pertwee, R.G. and Parsons, M.E. (2010) The Effects
of Delta-Tetrahydrocannabinol and Cannabidiol Alone and in Combination
on Damage, Inflammation and in Vitro Motility Disturbances in Rat
Colitis. British Journal of Pharmacology, 160, 712-723. http://dx.doi.org/10.1111/j.1476-5381.2010.00791.x |
| [14] | Gadó,
K. and Gigler, G. (1991) Zymosan Inflammation: A New Method Suitable
for Evaluating New Anti-Inflammatory Drugs. Agents and Actions, 32,
119-121. http://dx.doi.org/10.1007/BF01983335 |
| [15] | Grotenhermen, F. (2003) Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clinical Pharmacokinetics, 42, 327-360. http://dx.doi.org/10.2165/00003088-200342040-00003 |
| [16] | Rocha,
A.C., Fernandes, E.S., Quintao, N.L., Campos, M.M. and Calixto, J.B.
(2006) Relevance of Tumour Necrosis Factor-Alpha for the Inflammatory
and Nociceptive Responses Evoked by Carrageenan in the Mouse Paw.
British Journal of Pharmacology, 148, 688-695. http://dx.doi.org/10.1038/sj.bjp.0706775 |
| [17] | Romano,
B., Borrelli, F., Pagano, E., Cascio, M.G., Pertwee, R.G. and Izzo,
A.A. (2014) Inhibition of Colon Carcinogenesis by a Standardized
Cannabis Sativa Extract with High Content of Cannabidiol. Phytomedicine,
21, 631-639. http://dx.doi.org/10.1016/j.phymed.2013.11.006 |
| [18] | Capasso,
R., Aviello, G., Borrelli, F., Romano, B., Ferro, M., Castaldo, L.,
Montanaro, V., Altieri, V. and Izzo, A.A. (2011) Inhibitory Effect of
Standardized Cannabis Sativa Extract and Its Ingredient Cannabidiol on
Rat and Human Bladder Contractility. Urology, 77, 1006.e9-1006e15. http://dx.doi.org/10.1016/j.urology.2010.12.006 |
| [19] | De
Petrocellis, L., Ligresti, A., Schiano Moriello, A., Iappelli, M.,
Verde, R., Stott, C.G., Cristino, L., Orlando, P. and Di Marzo, V.
(2013) Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth in Vitro
and in Vivo: Pro-Apoptotic Effects and Underlying Mechanisms. British
Journal of Pharmacology, 168, 79-102. http://dx.doi.org/10.1111/j.1476-5381.2012.02027.x |
| [20] | Russo,
E.B. (2011) Taming THC: Potential Cannabis Synergy and
Phytocannabinoid-Terpenoid Entourage Effects. British Journal of
Pharmacology, 163, 1344-1364. http://dx.doi.org/10.1111/j.1476-5381.2011.01238.x |
| [21] | Wagner,
H. and Ulrich-Merzenich, G. (2009) Synergy Research: Approaching a New
Generation of Phytopharmaceuticals. Phytomedicine, 16, 97-110. http://dx.doi.org/10.1016/j.phymed.2008.12.018 eww150211lx |
评论
发表评论